Class Actions Seeks to Represent Untold Number of Caregivers Who Appealed Denials from the VA's Program of Comprehensive Assistance for Family Caregivers
WASHINGTON, Aug. 12,...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development...
SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, announced today that its lead candidate,...
LOS ANGELES, Aug. 10, 2025 /PRNewswire/ -- As 360° action cameras continue to evolve and push the boundaries of immersive storytelling, the tools that...
The Modern Playbook for Sponsorship and Cash Flow helps athletes get sponsored, grow their brand, and turn passion into profit.
Kelowna, BC, Aug. 9, 2025...
PHILADELPHIA, Aug. 8, 2025 /PRNewswire/ -- Berger Montague PC, a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been...
A roundup of the most newsworthy press releases from Cision Distribution this week
TORONTO, Aug. 8, 2025 /CNW/ - With thousands of press releases published...
World-renowned game creator and one of the most influential figures in the gaming industry will attend the Esports World Cup 2025 Festival and speak at...
World-renowned game creator and one of the most influential figures in the gaming industry will attend the Esports World Cup 2025 Festival and speak at...
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.) – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed case is captioned Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532 (D.N.J.).
Revises full year 2025 Net Sales, Adjusted EBITDA, and Adjusted Free Cash Flow guidanceReaffirms cost synergy capture targets of $200 million in 2025; $300...